High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy

Westermann, Dirk H; Studer, Urs E (2009). High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World journal of urology, 27(4), pp. 455-61. Berlin: Springer-Verlag 10.1007/s00345-009-0456-3

Preview

Text 345_2009_Article_456.pdf - Published Version Available under License Publisher holds Copyright. Download (280kB) | Preview

Testis cancer is the most frequent solid malignancy in young men. The majority of patients present with clinical stage I disease and about 50% of them are nonseminomatous germ cell tumors. In this initial stage of disease there is a subgroup of patients at high risk with a likelihood of more than 50% for relapse. Treatment options for these patients include: retroperitoneal lymph node dissection (RPLND), albeit 6-10% of patients will relapse outside the field of RPLND, active surveillance with even higher relapse rates and adjuvant chemotherapy. As most of these patients have the chance to become long-term survivors, avoidance of long-term side effects is of utmost importance. This review provides information on the potential of chemotherapy to achieve a higher chance of cure for patients with high-risk clinical stage I disease than its therapeutic alternatives and addresses toxicity and dose dependency.

Interest & Impact

Downloads

318 since deposited on 04 Oct 2013
55 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item